0
0
0
Pharmaceutical Research Transparency Act of 2023
12/15/2023, 4:07 PM
Summary of Bill S 1476
The Pharmaceutical Research Transparency Act of 2023, also known as Bill 118 s 1476, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to increase transparency in the pharmaceutical industry by requiring drug companies to disclose more information about their research and development processes.
Under this bill, pharmaceutical companies would be required to provide detailed information about the costs and funding sources of their research and development activities. This information would be made publicly available in order to increase transparency and accountability within the industry.
Additionally, the Pharmaceutical Research Transparency Act of 2023 would require drug companies to disclose any financial relationships they have with healthcare providers, researchers, or patient advocacy groups. This is intended to prevent conflicts of interest that could potentially influence the research and development of new drugs. Overall, the goal of this legislation is to ensure that the pharmaceutical industry operates in a transparent and ethical manner, ultimately leading to better outcomes for patients and the healthcare system as a whole.
Under this bill, pharmaceutical companies would be required to provide detailed information about the costs and funding sources of their research and development activities. This information would be made publicly available in order to increase transparency and accountability within the industry.
Additionally, the Pharmaceutical Research Transparency Act of 2023 would require drug companies to disclose any financial relationships they have with healthcare providers, researchers, or patient advocacy groups. This is intended to prevent conflicts of interest that could potentially influence the research and development of new drugs. Overall, the goal of this legislation is to ensure that the pharmaceutical industry operates in a transparent and ethical manner, ultimately leading to better outcomes for patients and the healthcare system as a whole.
Congressional Summary of S 1476
Pharmaceutical Research Transparency Act of 2023
This bill requires the disclosure of costs associated with clinical trials and pharmaceutical research and development.
Specifically, the National Institutes of Health must create a publicly available repository of cost data from certain clinical trials that test the efficacy of drugs, biological products, and devices in human subjects. For each applicable trial, the registry must, among other information, include the total and per patient cost of the trial, as well as costs for personnel, health care services, and other categories of expenditures. Information must be added to the registry within one year of the trial's completion.
The bill also requires drug manufacturers to include their research and development expenditures for drugs and biological products in annual disclosures made to the Securities and Exchange Commission.
Current Status of Bill S 1476
Bill S 1476 is currently in the status of Bill Introduced since May 9, 2023. Bill S 1476 was introduced during Congress 118 and was introduced to the Senate on May 9, 2023. Bill S 1476's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of May 9, 2023
Bipartisan Support of Bill S 1476
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
0Democrat Cosponsors
0Republican Cosponsors
0Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill S 1476
Primary Policy Focus
HealthComments
Sponsors and Cosponsors of S 1476
Latest Bills
To authorize the Secretary of Education, in collaboration with the Secretary of Health and Human Services, to establish an interagency advisory Commission on Advancing Restorative Justice in Elementary and Secondary Education, and for other purposes.
Bill HR 8360April 17, 2026
To amend the Higher Education Act of 1965 to remove all adverse credit history related to a loan from the credit history of a borrower who has rehabilitated the loan.
Bill HR 8361April 17, 2026
To reauthorize the YouthBuild program, and for other purposes.
Bill HR 8333April 17, 2026
To raise the Foreign Service mandatory retirement age by aligning it with the Social Security Full Retirement Age, and for other purposes.
Bill HR 8346April 17, 2026
To amend the FISA Amendments Act of 2008 to extend the authorities of title VII of the Foreign Intelligence Surveillance Act of 1978 through April 30, 2026, and for other purposes.
Bill HR 8322April 17, 2026
To amend title II of the Social Security Act to repeal the retirement earnings test, and for other purposes.
Bill HR 8344April 17, 2026
To amend section 133 of title 23, United States Code, to remove a certain State funding set-aside for transportation alternative programs, and for other purposes.
Bill HR 8349April 17, 2026
To amend title XI of the Social Security Act to require the Center for Medicare and Medicaid Innovation to test a model to reduce chronic diseases by using accountable produce is medicine.
Bill HR 8355April 17, 2026
To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.
Bill HR 8339April 17, 2026
Supporting the designation of the week of April 11 through April 17, 2026, as "Black Maternal Health Week", founded by Black Mamas Matter Alliance, Inc. (BMMA), to bring national attention to the maternal and reproductive health crisis in the United States and the importance of reducing maternal mortality and morbidity among Black women and birthing people.
Bill HRES 1183April 17, 2026
Pharmaceutical Research Transparency Act of 2023
Bill HR 3160December 15, 2023